Literature DB >> 20518734

Expression, purification, and characterization of a functional mutant recombinant human interleukin-2.

Mingjun Liu1, Bin Wang, Guirong Sun, Dongmeng Qian, Zhiyong Yan, Xuxia Song, Shouyi Ding.   

Abstract

In the current study, a mutant recombinant human interleukin-2 (MhIL-2) was generated using site-directed mutagenesis. The bacteria transformed with plasmid pET15b-MhIL-2 were cultured in LB medium containing 0.6mM IPTG for 8 hours at 27°C. Approximately 90% of His-MhIL-2 was efficiently expressed in soluble form. Purification efficiency was optimized using a number of strategies, including nickel ion chelating chromatography, desalting chromatography, thrombin cleavage and Superdex 75 gel filtration chromatography. The final product had >95% purity. PBMCs, CD4+ and CD8+ T cell proliferation assays revealed that one such mutant has identical functional property to the wild-type hIL-2. In summary, we generated a mutant hIL-2 that is functionally identical to wild-type hIL-2.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20518734     DOI: 10.2174/092986610792231474

Source DB:  PubMed          Journal:  Protein Pept Lett        ISSN: 0929-8665            Impact factor:   1.890


  3 in total

1.  Construction of the plasmid coding for the expression of the EGFP-M-IL-2(88Arg, 125Ala) fusion protein and the anti-tumor effects exerted by the fusion protein in HeLa-60 cells.

Authors:  Guangcan Shao; Dongmeng Qian; Haitao Wang; Zhiyong Yan; Ming Hu; Tongmei Wang; Bin Wang
Journal:  Oncol Lett       Date:  2015-04-20       Impact factor: 2.967

2.  Expression, Identification and Characterize of CD25-Binding Epitope Modified Human IL-2 in Pichia pastoris.

Authors:  S Wang; H T Li; Y H Liu; Y Z Zhu; W H Wang; Y X An; L G Miao
Journal:  Indian J Microbiol       Date:  2013-02-07       Impact factor: 2.461

3.  Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.

Authors:  Mingjun Liu; Haitao Wang; Linjie Liu; Bin Wang; Guirong Sun
Journal:  J Transl Med       Date:  2016-06-01       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.